Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease
Sara Ashorn MS
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTeemu Honkanen MSc
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Department of Pathology, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorKaija-Leena Kolho MD, PhD
Hospital for Children and Adolescents, Helsinki, Finland
Search for more papers by this authorMerja Ashorn MD, PhD
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Department of Paediatrics, Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTuuli Välineva MSc
Institute of Medical Technology, University of Tampere, Tampere, Finland
Search for more papers by this authorBo Wei PhD
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, USA
Search for more papers by this authorJonathan Braun MD, PhD
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, USA
Search for more papers by this authorImmo Rantala MD, PhD
Department of Pathology, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTiina Luukkaala MSc
Science Center, Pirkanmaa University Hospital District and Tampere School of Public Health, University of Tampere, Tampere, Finland
Search for more papers by this authorCorresponding Author
Sari Iltanen MD, PhD
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Medical School, Paediatric Research Centre, Building FM3, FIN-33014 University of Tampere, Tampere, FinlandSearch for more papers by this authorSara Ashorn MS
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTeemu Honkanen MSc
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Department of Pathology, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorKaija-Leena Kolho MD, PhD
Hospital for Children and Adolescents, Helsinki, Finland
Search for more papers by this authorMerja Ashorn MD, PhD
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Department of Paediatrics, Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTuuli Välineva MSc
Institute of Medical Technology, University of Tampere, Tampere, Finland
Search for more papers by this authorBo Wei PhD
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, USA
Search for more papers by this authorJonathan Braun MD, PhD
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, USA
Search for more papers by this authorImmo Rantala MD, PhD
Department of Pathology, University of Tampere and Tampere University Hospital, Tampere, Finland
Search for more papers by this authorTiina Luukkaala MSc
Science Center, Pirkanmaa University Hospital District and Tampere School of Public Health, University of Tampere, Tampere, Finland
Search for more papers by this authorCorresponding Author
Sari Iltanen MD, PhD
Paediatric Research Centre, University of Tampere and Tampere University Hospital, Tampere, Finland
Medical School, Paediatric Research Centre, Building FM3, FIN-33014 University of Tampere, Tampere, FinlandSearch for more papers by this authorAbstract
Background: Noninvasive, sensitive, and specific tools for early identification of chronic inflammatory bowel disease (IBD) are needed for clinical practice. The aim was to identify new noninvasive test combinations for characterization of IBD in children and adolescents by comparing serological responses to microbial antigens and fecal calprotectin, a new promising marker for intestinal inflammation.
Methods: Our study included 73 children who underwent endoscopies because of suspicion of IBD. Their sera were tested for antibodies to the Pseudomonas fluorescens-associated sequence I2, a Bacteroides caccae TonB-linked outer membrane protein, OmpW, and anti-Saccharomyces cerevisiae (ASCA). Simultaneously, samples for fecal calprotectin measurements were obtained from 55 subjects.
Results: IBD was diagnosed in 60 patients (Crohn's disease [CD] in 18 patients, ulcerative colitis [UC] in 36, and indeterminate colitis [IC] in 6). Thirteen children had a non-IBD disease. Fecal calprotectin levels were elevated (≥100 μg/g) more frequently in IBD patients (89%, 39/44) compared to non-IBD cases (9%, 1/11, P < 0.001). ASCA antibodies in sera were detected in 67% (12/18) of patients with CD, in 14% (5/36) of the children with UC, and in 50% (3/6) of patients with IC. Seroreactivity for I2 was observed in 42% of the IBD patients, this frequency being higher than in non-IBD cases (7.7% seropositive; P = 0.025). Serum anti-I2 IgA levels (median absorbances) were higher in those with IBD compared to those without gut inflammation (P = 0.039). The combination of the measurements of fecal calprotectin and serological responses to microbial antigens (ASCA, I2, and OmpW) identified 100% of CD patients (sensitivity 100%, specificity 36%, positive predictive value [PPV] 66%, negative predictive value [NPV] 100%) and 89% of UC patients (sensitivity 89%, specificity 36%, PPV 77%, NPV 57%).
Conclusions: Increased levels of serological responses to microbial antigens (ASCA, I2, and OmpW) and fecal calprotectin are evident in both CD and UC patients. The combination of these markers provides valuable, noninvasive tools for the diagnosis of IBD.
(Inflamm Bowel Dis 2008)
REFERENCES
- 1 Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50–54.
- 2 Tibble JA, Sighthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15–22.
- 3 Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 14–22.
- 4 Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14: 823–825.
- 5 Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002; 91: 45–50.
- 6 Wassell J, Dolwani S, Metzner M, et al. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem. 2004; 41: 230–232.
- 7 Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007; 381: 63–68.
- 8 McKenzie H, Main J, Pennington CR, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut. 1990; 31: 536–538.
- 9 Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47: 487–496.
- 10 Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001; 96: 758–765.
- 11 Bartunkova J, Kolarova I, Sediva A, et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cervisie antibodies, and specific IgE to food allergens in children with inflammatory bowel disease. Clin Immunol. 2002; 102: 162–168.
- 12 Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006; 101: 2410–2422.
- 13 Desplat-Jego S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007; 13: 2312–2318.
- 14 Saxon A, Shanahan F, Landers CJ, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86: 202–210.
- 15 Cohavy O, Harth G, Horwitz M, et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun. 1999; 67: 6510–6517.
- 16 Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000; 68: 1542–1548.
- 17 Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005; 54: 1232–1236.
- 18 Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998; 93: 1306–1310.
- 19 Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001; 7: 8–15.
- 20 Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000; 119: 23–31.
- 21 Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immunol. 2002; 70: 6567–6575.
- 22 Wei B, Dalwadi H, Gordon LK, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun. 2001; 69: 6044–6054.
- 23 Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002; 123: 689–699.
- 24 Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004; 99: 2235–2241.
- 25 Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin Vaccine Immunol. 2006; 13: 655–660.
- 26 Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006; 12: 389–394.
- 27 Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99: 2376–2384.
- 28 Evans CM, Beattie RM, Walker-Smith JA. Inflammatory bowel disease in childhood. In: RN Allan, JM Rhodes, SB Hanauer, eds. Inflammatory Bowel Diseases. 3rd ed. New York: Churchill Livingstone; 1997. : 647–670.
- 29 Dixon FM, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996; 20: 1161–1181.
- 30 Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006; 41: 720–725.
- 31 Amati L, Passeri ME, Selicato F, et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol Immunotoxicol. 2006; 28: 665–681.
- 32 von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803–813
- 33 Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007; 13: 24–32.
- 34 Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007; 13: 2028–2036.
- 35 Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007; 5: 602–608.
- 36 Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360–367.
- 37 Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004; 113: 1296–1306.
- 38 Targan SR, Landers CJ, Yang H, et al. Antibodies to Cbir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 2020–2028.
- 39 Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006; 52: 171–181.
- 40 Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126: 414–424.
- 41 Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56: 1394–1403.
- 42 Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccaharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for surgery. Gut. 2004; 53: 1117–1122.
